Bodri Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bodri Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-300,000	Closed	-$9.53M	–	46
2014 Q4	$9.53M	Hold	300,000	–	–	4.38%	5
2014 Q3	$7.43M	Buy	300,000 +175,000	+140%	+$4.09M	3.6%	6
2014 Q2	$2.82M	Sell	125,000 -75,000	-38%	-$1.57M	1.46%	25
2014 Q1	$4.87M	Buy	200,000 +25,000	+14%	+$632K	2.43%	14
2013 Q4	$4.37M	Buy	175,000 +25,000	+17%	+$590K	2.12%	17
2013 Q3	$4.12M	Buy	150,000 +50,000	+50%	+$1.05M	2.4%	16
2013 Q2	$1.81M	Buy	+100,000	New	+$1.38M	1.12%	35

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bodri Capital Management's ACAD Position: Q1 2015 in Review

Bodri Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2015, closing a stake of 300,000 shares — an estimated $9.53M sold.

Bodri Capital Management first reported a position in ACAD in Q2 2013 and held it in 7 quarters. The position peaked at $9.53M in Q4 2014. 193 funds tracked by Wall St. Rank hold ACAD as of Q1 2015.

Bodri Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Bodri Capital Management sold 300,000 Acadia Pharmaceuticals shares in Q1 2015, an estimated $9.53M.
Bodri Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Bodri Capital Management's Acadia Pharmaceuticals position peaked at $9.53M in Q4 2014.
193 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2015.

Based on Bodri Capital Management's 13F filing for Q1 2015, filed 15 May 2015.